OraSure Technologies, a company known for its innovative point-of-need and home diagnostic tests, has announced the acquisition of Sherlock Biosciences, a pioneering health firm focused on next-generation diagnostics. This move will significantly enhance OraSure’s range of diagnostic solutions by adding Sherlock’s advanced molecular diagnostic platform, which delivers rapid results with high accuracy in a convenient, disposable format. The new technology is especially suited for at-home testing.
Sherlock’s molecular self-test for Chlamydia Trachomatis (CT) and Neisseria Gonorrhoeae (NG), currently in clinical studies, will be an important addition to OraSure’s portfolio of rapid diagnostics for sexually transmitted infections (STIs). Once regulatory approval is received, the self-test is expected to provide results in under 30 minutes, using isothermal amplification technology to analyze DNA and RNA from self-collected swabs. The company is optimistic that this new product will make a significant impact on the market for STI testing.
Sherlock’s CT/NG test is expected to be submitted to the FDA for approval by the end of 2025. Once approved, the test could start contributing to OraSure’s revenue in 2026. The company is confident that this acquisition, along with its existing infrastructure and customer base, will allow it to expand its reach in the growing STI testing market. The total addressable market for CT/NG testing in the U.S. alone is estimated at more than $1.5 billion, with the potential for significant market expansion thanks to the affordable, at-home nature of the self-test.
In addition to the CT/NG test, Sherlock is developing a range of other molecular diagnostic tests, as well as innovative technology platforms like Ambient Temperature Amplification and CRISPR-based systems. These technologies could further reduce costs and enhance the performance of its diagnostics, broadening the potential applications in healthcare.
OraSure sees this acquisition as a key step in its innovation strategy. Carrie Eglinton Manner, President and CEO of OraSure, commented, “The acquisition of Sherlock represents the next step in OTI’s innovation strategy. Sherlock brings valuable capabilities with an advanced molecular platform that aims to deliver lab-like accuracy in a format that expands access to diagnostic insights through convenient, effortless tests. We are excited to welcome Sherlock’s talented team to OTI and believe that Sherlock’s unique capabilities will contribute significantly to the expansion of our pipeline of diagnostic tests in infectious disease, sexual health, and beyond.”
This acquisition underscores OraSure’s commitment to providing innovative and accessible diagnostic solutions, especially in the areas of sexual health and infectious diseases. With the addition of Sherlock’s cutting-edge technology, OraSure is well-positioned to continue its growth and improve healthcare access for consumers and providers alike.